Evidence map›Paper›PMID 26108169›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2015

Defining optimal control of chemotherapy-induced nausea and vomiting-based on patients' experience.

Catalina Hernandez Torres, Sasha Mazzarello, Terry Ng, George Dranitsaris, Brian Hutton, Stephanie Smith, Amy Munro, Carmel Jacobs, Mark Clemons

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Outcomes of chemotherapy-induced nausea and vomiting guideline adherence in pediatric and adult patients: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Effects of ginger adjunct to the standard prophylaxis on reducing carboplatin and paclitaxel-induced nausea vomiting: a randomized controlled study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Review
  13. Step count and symptom severity during cancer treatment using the Symptom Care at Home digital platform.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  14. Article
  15. Review
  16. Article
  17. A retrospective study on chemotherapy-induced nausea and vomiting in highly/moderately emetogenic chemotherapy: incidence and prescribing practice.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Article
  18. Clinical utility of a prediction tool to differentiate between breast cancer patients at high or low risk of chemotherapy-induced nausea and vomiting.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Catalina Hernandez TorresDivision of Medical Oncology and Department of Medicine, University of Ottawa, Ottawa, Canada.
Sasha MazzarelloCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Terry NgDivision of Medical Oncology and Department of Medicine, University of Ottawa, Ottawa, Canada.
George Dranitsaris, Toronto, Canada.
Brian HuttonClinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Stephanie SmithCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Amy MunroCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Carmel JacobsDivision of Medical Oncology and Department of Medicine, University of Ottawa, Ottawa, Canada.
Mark ClemonsDivision of Medical Oncology and Department of Medicine, University of Ottawa, Ottawa, Canada. mclemons@toh.on.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeA considerable challenge when comparing antiemetic trials for chemotherapy-induced nausea and vomiting (CINV) is the large number of outcome measures for nausea and vomiting. The objective of this study is to determine the optimal definition of CINV control from the patients' perspective.

methodsPatients with early-stage breast cancer who had received anthracycline-cyclophosphamide-based chemotherapy were surveyed. They were asked about their experiences of CINV and perceptions of different CINV assessment tools.

resultsOf 201 patients approached, 168 (83 %) completed the survey. Patients consistently ranked nausea over vomiting as the "worst side effect from chemotherapy." Despite the use of multi-agent antiemetic regimens, 71 % of patients experienced nausea and 26 % vomiting. Only 57 % of patients with any nausea or vomiting took rescue medications and only then when the symptom was severe. Most (76 %) patients believed that the primary end point of antiemetic trials should include the absence of both nausea and vomiting. Patients felt that CINV should be evaluated for the overall period post chemotherapy (i.e., days 1-5) and not simply the acute (the first 24 h) or delayed (days 2-5) periods.

conclusionsPatients strongly favored a CINV end point that includes the absence of both nausea and vomiting. Patients' experience with CINV is underestimated when nausea is not included in composite end points. "Use of rescue medication," a commonly used surrogate for emesis control, is inappropriate as it underestimates nausea. A standardized primary end point that includes nausea is essential if CINV control is to be improved.

Indexed as

Patient PreferenceAdultAgedAnthracyclinesAntiemeticsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCyclophosphamideFemaleHumansMiddle AgedNauseaSurveys and QuestionnairesTime FactorsVomitingAnthracyclinesAntiemeticsAntineoplastic AgentsCyclophosphamideBreast cancerCINVEnd pointsPatientPerception

Identifiers

PMID26108169

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.